Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medtronic has presented five-year findings of Endeavor drug-eluting stent (DES) as a treatment for coronary artery disease at the American College of Cardiology’s 59th Scientific Session.
Subscribe to our email newsletter
Medtronic said the E-Pooled analysis, which included five-year data from the Endeavor I (E-I), Endeavor II (E-II), E-II Continued Access (CA), and Endeavor III (E-III) clinical studies, and three-year data from the Endeavor IV (E-IV) and Endeavor Pharmacokinetics (E-PK) clinical studies, demonstrated consistency in clinical results across multiple studies.
The E-Pooled analysis included patients who were treated with the Endeavor DES in E-I, E-PK, E-II, E-II CA, E-III and E-IV; it uses the Medtronic Driver bare-metal stent (BMS) control arm of E-II as a comparator.
The E-Pooled analysis also included clinical data on more than 2,100 Endeavor patients from six rigorously conducted clinical trials distinguished by 100% patient monitoring, 100% source data verification and independent, blinded event adjudication performed at the Harvard Clinical Research Institute.
The data released were the final five-year results from the Endeavor III randomised controlled trial comparing the Endeavor DES to the Cypher DES (from Johnson & Johnson’s Cordis) with a primary angiographic endpoint of late lumen loss at eight months.
E-III five-year results showed low rates of MACE, TLR and ST for Endeavor patients which were consistent with the E-Pooled analysis. They also revealed prominent difference in rates of CD/MI as well as a trend toward lower MACE in favor of the Endeavor DES.
E-III five-year outcomes confirmed the phenomena of late catch-up in TLR with the Cypher DES: From years 1–5 of follow up, the data showed a TLR increase of 86% with the Cypher DES compared to 21% with the Endeavor stent. The difference in TLR rates after the first year of patient follow up in E-III driven similar overall TLR rates at five years. Additionally, MACE increased in the Cypher patients by 173% compared to 74 % in the Endeavor patients, the company reported.
David Kandzari, co-principal investigator of E-III and E-IV of Medtronic, said: “The consistency of results across these well conducted clinical trials is remarkable. The Endeavor stent has demonstrated a very compelling safety and efficacy profile wherein there is a very low likelihood that patients treated with the Endeavor stent will experience late stent clotting or the need for a repeat procedure beyond the first year of follow up.”